لخّصلي

– Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J (2015).Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. doi: 10.1038 2. – Murray B.O., Flores C., Williams C., Flusberg D.A., Marr E.E., Kwiatkowska K.M., Charest J.L., Isenberg B.C., Rohn J.R. (2021).Recurrent Urinary Tract Infection: A Mystery in Search of Better Model Systems. Front Cell. Infect. Microbiol.doi: 10.3389 3. – Subashchandrabose S., Mobley H.L. (2015).Virulence and Fitness Determinants of Uropathogenic Escherichia coli. Microbiol. Spectrdoi:10.1128 4. – Schwab S. Jobin K.KurtsC. (2017)(1977).(1983).Urinary tract infection: Recent insight into the evolutionary arms race between uropathogenic Escherichia coli and our immune system. Nephrol. Dial. Transplant. doi: 10.1093 / 5. – lSpaulding C.N., Hultgren S.J. (2016).Adhesive pili in UTI pathogenesis and drug development. Pathogens. . doi: 10.3390/ 6– pConover M.S., Hadjifrangiskou M., Palermo J.J., Hibbing M.E., Dodson K.W., Hultgren S.J. (2016).Metabolic requirements of Escherichia coli in intracellular bacterial communities during urinary tract infection pathogenesis. mBio. doi: 10.1128 / 7– Tamadonfar K.O., Omattage N.S., Spaulding C.N., Hultgren S.J.(2019) .Reaching the end of the line: Urinary tract infections. Microbiol. Spectr. doi: 10.1128/ 8– Lane M.C., Alteri C.J., Smith S.N., Mobley H.L. (2007)Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc. Natl. Acad. Sci. USA. . doi: 10.1073 20 9–Soto S.M. (2014).Importance of Biofilms in Urinary Tract Infections: New Therapeutic Approaches. Adv. Biol. doi: 10.1155/ 10–Tenaillon O, Skurnik D, Picard B, Denamur E (March 2010). “The population genetics of commensal Escherichia coli”. Nature Reviews microbiology8 dio:10.1038/nrmicro2298. 11–Singleton P (199l9). Bacteria in Biology, Biotechnology and Medicine (5th ed.). Wiley. pp. 444–54. ISBN 978-0-471-98880-9. 12–Bentley R, Meganathan R (September 1982). “Biosynthesis of vitamin K (menaquinone) in bacteria”. Microbiological Reviews. 46 (3): 241–80. doi:10.1128 / 13. –Feng P, Weagant S, Grant M (1 September 2002). 19 May 2009. Retrieved 25 January 2007. “Enumeration of Escherichia coli and the Coliform Bacteria”. Bacteriological Analytical Manual (8th ed.). FDA/Center for Food Safety & Applied Nutrition. Archived from the original . Bartoletti R., Cai T., Wagenlehner F.M., Naber K., Bjerklund Johansen . – 14 Infection and Treatment of Urinary Tract . ) 16 0 (2 T.E. AntibioticStewardship.Eur.Urol.doi:10.1016 15–Ong L.T. (2020).Antibiotics for complicated urinary tract infection and acute pyelonephritis: A systematic review. World J. Clin. Infect. Dis.Doi.10.5495 16–Cai T., Palagin I., Brunelli R., Cipelli R., Pellini E., Truzzi J.C., Van Bruwaene S. (2020).Office-based approach to urinary tract infections in 50 000 patients: Results from the REWIND study. Int. J.Antimicrob.Agents.doi: 10.1016 . . 21 17– Gonzalez M.J., Da Cunda P., Notejane M., Zunino P Scavone P., Robino L.(2019). Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic Escherichia coli isolated from patients with urinary tract infection. Pahog. . 18–.Sharma K., Dhar N., Thacker V.V., Simonet T.M., Signorino-Gelo F., Knott G.W., McKinney J.D. (2021).Dynamic persistence of UPEC intracellular bacterial communities in a human bladder-chip model of urinary tract infection. Elife.Gpp doi: 10.7554/eLife.66481. 19–Harding C., Mossop H., Homer T., Chadwick T., King W., Carnell S., Lecouturier J., Abouhajar A., Vale L., Watson G.,(2022). et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: Multicentre, open label, randomised, non-inferiority trial. BMJ. 376:e068229. doi: 10.1136 . 20.–Mazzariol A., Bazaj A., Cornaglia G. (2017).Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: A review. J. Chemother. doi: 10.1080/1120009X..1380395 . 21. –Lavigne J.P., Thibault M., Costa P., Combescure C., Sotto A., Cariou G., Ronco E., Lanotte P., Bruyère F., Coloby P., et al.(2016). Resistance and virulence potential of uropathogenic Escherichia coli strains isolated from patients hospitalized in urology departments: A Frenc prospective multicentre study. J. Med. Microbiol. Doi: 10.1099/jmm.0.000247 . 22–Bandyopadhyay D., Mukherjee M. (2022).Combination of bactericidal antibiotics and inhibitors of Universal stress protein A (UspA): A potential therapeutic alternative against multidrug resistant Escherichia coli in urinary tract infections. J. Antibiotics. doi:

– Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J
(2015).Urinary tract infections: Epidemiology, mechanisms of infection
and treatment options. Nat. Rev. Microbiol. doi: 10.1038
2.
– Murray B.O., Flores C., Williams C., Flusberg D.A., Marr E.E.,
Kwiatkowska K.M., Charest J.L., Isenberg B.C., Rohn J.R.
(2021).Recurrent Urinary Tract Infection: A Mystery in Search of Better
Model Systems. Front Cell. Infect. Microbiol.doi: 10.3389
3.
– Subashchandrabose S., Mobley H.L. (2015).Virulence and Fitness
Determinants of Uropathogenic Escherichia coli. Microbiol.
Spectrdoi:10.1128
4.
– Schwab S. Jobin K.KurtsC. (2017)(1977).(1983).Urinary tract
infection: Recent insight into the evolutionary arms race between
uropathogenic Escherichia coli and our immune system. Nephrol. Dial.
Transplant. doi: 10.1093 /
5.
– lSpaulding C.N., Hultgren S.J. (2016).Adhesive pili in UTI
pathogenesis and drug development. Pathogens. . doi: 10.3390/
6– pConover M.S., Hadjifrangiskou M., Palermo J.J., Hibbing M.E.,
Dodson K.W., Hultgren S.J. (2016).Metabolic requirements of
Escherichia coli in intracellular bacterial communities during urinary
tract infection pathogenesis. mBio. doi: 10.1128 /
7– Tamadonfar K.O., Omattage N.S., Spaulding C.N., Hultgren
S.J.(2019) .Reaching the end of the line: Urinary tract infections.
Microbiol. Spectr. doi: 10.1128/
8– Lane M.C., Alteri C.J., Smith S.N., Mobley H.L. (2007)Expression
of flagella is coincident with uropathogenic Escherichia coli ascension
to the upper urinary tract. Proc. Natl. Acad. Sci. USA. . doi: 10.1073
20
9–Soto S.M. (2014).Importance of Biofilms in Urinary Tract Infections:
New Therapeutic Approaches. Adv. Biol. doi: 10.1155/
10–Tenaillon O, Skurnik D, Picard B, Denamur E (March 2010). “The
population genetics of commensal Escherichia coli”. Nature Reviews
microbiology8 dio:10.1038/nrmicro2298.
11–Singleton P (199l9). Bacteria in Biology, Biotechnology and Medicine
(5th ed.). Wiley. pp. 444–54. ISBN 978-0-471-98880-9.
12–Bentley R, Meganathan R (September 1982). “Biosynthesis of vitamin
K (menaquinone) in bacteria”. Microbiological Reviews. 46 (3): 241–80.
doi:10.1128 /
13. –Feng P, Weagant S, Grant M (1 September 2002). 19 May 2009.
Retrieved 25 January 2007. “Enumeration of Escherichia coli and the
Coliform Bacteria”. Bacteriological Analytical Manual (8th ed.).
FDA/Center for Food Safety & Applied Nutrition. Archived from the
original .
Bartoletti R., Cai T., Wagenlehner F.M., Naber K., Bjerklund Johansen
.
– 14
Infection and Treatment of Urinary Tract .
)
16 0
(2 T.E.
AntibioticStewardship.Eur.Urol.doi:10.1016
15–Ong L.T. (2020).Antibiotics for complicated urinary tract infection and
acute pyelonephritis: A systematic review. World J. Clin. Infect.
Dis.Doi.10.5495
16–Cai T., Palagin I., Brunelli R., Cipelli R., Pellini E., Truzzi J.C.,
Van Bruwaene S. (2020).Office-based approach to urinary tract
infections in 50 000 patients: Results from the REWIND study. Int.
J.Antimicrob.Agents.doi: 10.1016 .
.
21
17– Gonzalez M.J., Da Cunda P., Notejane M., Zunino P Scavone P.,
Robino L.(2019). Fosfomycin tromethamine activity on biofilm and
intracellular bacterial communities produced by uropathogenic
Escherichia coli isolated from patients with urinary tract infection. Pahog.
.
18–.Sharma K., Dhar N., Thacker V.V., Simonet T.M., Signorino-Gelo F.,
Knott G.W., McKinney J.D. (2021).Dynamic persistence of UPEC
intracellular bacterial communities in a human bladder-chip model of
urinary tract infection. Elife.Gpp doi: 10.7554/eLife.66481.
19–Harding C., Mossop H., Homer T., Chadwick T., King W., Carnell S.,
Lecouturier J., Abouhajar A., Vale L., Watson G.,(2022). et al. Alternative
to prophylactic antibiotics for the treatment of recurrent urinary tract
infections in women: Multicentre, open label, randomised, non-inferiority
trial. BMJ. 376:e068229. doi: 10.1136 .
20.–Mazzariol A., Bazaj A., Cornaglia G. (2017).Multi-drug-resistant
Gram-negative bacteria causing urinary tract infections: A review. J.
Chemother. doi: 10.1080/1120009X..1380395 .
21.
–Lavigne J.P., Thibault M., Costa P., Combescure C., Sotto A., Cariou
G., Ronco E., Lanotte P., Bruyère F., Coloby P., et al.(2016). Resistance
and virulence potential of uropathogenic Escherichia coli strains isolated
from patients hospitalized in urology departments: A Frenc
prospective multicentre study. J. Med. Microbiol. Doi:
10.1099/jmm.0.000247
.
22–Bandyopadhyay D., Mukherjee M. (2022).Combination of
bactericidal antibiotics and inhibitors of Universal stress protein A
(UspA): A potential therapeutic alternative against multidrug resistant
Escherichia coli in urinary tract infections. J. Antibiotics. doi: